SD Biosensor

SD Biosensor Forward P/E

The Forward P/E Ratio of SD Biosensor (137310.KS) as of Oct 21, 2026 is -1.74. In the previous year, Forward P/E Ratio was -9.08 — a change of -80.78% (higher).

Forward P/E

-1.74

YoY

-80.78%

Last updated:

Forward P/E Ratio of SD Biosensor is 2025 -1.74 . Forward P/E Ratio of SD Biosensor was 2024 -9.08 . It decreases by -80.78% higher compared to the previous year.

The SD Biosensor Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
283.38 KRW
Jan 1, 2020
1.45 KRW
Jan 1, 2021
0.84 KRW
Jan 1, 2022
0.98 KRW
Jan 1, 2023
-1.91 KRW
Jan 1, 2024
-9.08 KRW
Jan 1, 2025
-1.74 KRW
The SD Biosensor Forward P/E history
YEARForward P/EYoY
-1.74-80.78%
-9.08+375.26%
-1.91-294.86%
0.98+16.83%
0.84-42.18%
1.45-99.49%
283.38—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SD Biosensor Stock analysis

What does SD Biosensor do? SD Biosensor Inc generates revenue through the development and manufacturing of cholesterol and blood glucose testing equipment. The company sells rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, and enzyme immunological reaction diagnosis products. These products are distributed domestically and internationally, targeting healthcare providers and consumers in the immunochemical, molecular, and point-of-care diagnosis sectors. The firm focuses on self blood glucose measurement and other diagnostic solutions for medical use. The company's product portfolio includes POCTs, which are used for point-of-care testing in medical settings. SD Biosensor Inc's offerings serve both the domestic market and overseas markets, with a strong emphasis on diagnostic equipment for healthcare applications. Their business model relies on the sale of these specialized medical devices to hospitals, clinics, and individual consumers seeking home health monitoring solutions. Revenue streams are derived from the research, development, and sale of diagnostic products, including immunochemical and molecular diagnosis tools. The firm's products are designed for use in clinical and self-testing environments, supporting both professional healthcare services and personal health management. SD Biosensor Inc's market segments include healthcare institutions and end-users requiring diagnostic testing for cholesterol, blood glucose, and other medical conditions. SD Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SD Biosensor stock

Forward P/E Ratio of SD Biosensor is -1.74 in 2025.

Forward P/E Ratio of SD Biosensor changed from -9.08 to -1.74, representing a -80.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio SD Biosensor since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's SD Biosensor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SD Biosensor

All Key Metrics — SD Biosensor